The generic name for Uzedy is risankizumab [1].
What is risankizumab used to treat?
Risankizumab is a prescription medication used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1]. It is also indicated for active psoriatic arthritis and moderately to severely active Crohn's disease [1].
How does risankizumab work?
Risankizumab is an interleukin-17A (IL-17A) antagonist [1]. By blocking IL-17A, it reduces inflammation associated with certain autoimmune conditions like psoriasis and psoriatic arthritis [1].
When did Uzedy first receive approval?
Uzedy was approved by the U.S. Food and Drug Administration (FDA) in January 2023 [2].
What are the potential side effects of risankizumab?
Common side effects of risankizumab include upper respiratory infections, headache, fatigue, injection site reactions, and fungal skin infections [1]. More serious side effects can include increased risk of infections, allergic reactions, and liver problems [1].
How is Uzedy administered?
Uzedy is administered as a subcutaneous injection [1].
What is the difference between Uzedy and other risankizumab brands?
Uzedy is a specific brand name for risankizumab. Skyrizi is another brand name for the same active ingredient, risankizumab [3]. The difference may lie in the manufacturer or formulation, but the active drug remains the same.
When does the patent for Uzedy expire?
Information on specific patent expiry dates for Uzedy is typically available through specialized databases. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals [4].
Who manufactures Uzedy?
Uzedy is manufactured by AbbVie [2].
What are the treatment costs for Uzedy?
The cost of Uzedy can vary significantly depending on insurance coverage, pharmacy, and any patient assistance programs. Information regarding pricing is best obtained from healthcare providers or pharmaceutical company websites.
Are there alternative treatments for plaque psoriasis, psoriatic arthritis, or Crohn's disease?
Yes, there are several alternative treatment options available for these conditions, including other biologic medications (such as TNF inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors), oral medications, and phototherapy [1].
What is the clinical efficacy of risankizumab?
Clinical trials have demonstrated that risankizumab is effective in achieving and maintaining skin clearance in patients with plaque psoriasis, leading to significant improvements in disease activity for psoriatic arthritis and Crohn's disease [1].
What is the regulatory status of Uzedy in other countries?
Uzedy is also approved in other regions, with Skyrizi being the established global brand for risankizumab [3].
How does risankizumab compare to other IL-17 inhibitors?
Risankizumab, like other IL-17 inhibitors, targets the IL-17 pathway to reduce inflammation. However, specific efficacy, safety profiles, and dosing regimens can differ between various IL-17 inhibitors.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761172s000lbl.pdf
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-mo-decisions
[3] https://www.skyrizi.com/
[4] https://www.drugpatentwatch.com/